Kliničke studije za Рак дојке u državi Тексас
176 studija za Рак дојке traži učesnike na lokacijama u državi Тексас.
Gradovi u državi Тексас
- Houston126 студија
- Dallas54 студија
- San Antonio45 студија
- Austin15 студија
- Fort Worth14 студија
- League City12 студија
- The Woodlands11 студија
- Sugar Land8 студија
- Irving8 студија
- El Paso7 студија
- Lewisville6 студија
- Lubbock6 студија
- Tyler5 студија
- McAllen4 студија
- Amarillo4 студија
- Killeen4 студија
- Baytown3 студија
- Abilene3 студија
- Denton3 студија
- Arlington3 студија
- Cypress3 студија
Zvanični tekst studije (na engleskom)
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- NEXT Houston, Galveston
- NEXT Oncology - PARENT, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07360314Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Baylor College of Medicine, Houston
- MD Anderson Cancer Center, Houston
- Harris Health System - Smith Clinic, Houston
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT05696626A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Renovatio Clinical - El Paso, El Paso
- JPS Health Network, Fort Worth
- Renovatio Clinical, The Woodlands
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT05894239A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- Oncology Consultants PA, Houston
Тражи се учесникФаза 1
Узраст од 18 до 55 · Жене · Ажурирано 12. 11. 2026. · NCT07310420Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
- M D Anderson Cancer Center, Houston
Тражи се учесник
Узраст 18 и старији · Жене · Ажурирано 12. 11. 2026. · NCT05649072Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Texas Oncology - DFW ( Site 8000), Dallas
- Houston Methodist Hospital ( Site 0022), Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06797635Multi-center MRD Registry for Inflammatory Breast Cancer
- MD Anderson Cancer Center, Houston
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06966050An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
- Next Oncology Austin, Austin
- The University of Texas Md Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07222267BostonGene and Exigent Genomic INsight Study
- Oncology Consultants, Houston
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06272864S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- UT Southwestern Clinical Center at Richardson/Plano, Richardson
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT03418961Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
- UT MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 12 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT05372640Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
- Research Facility, Dallas
- Research Facility, Houston
Тражи се учесникФаза 1/2
Сви узрасти · Оба пола · Ажурирано 12. 11. 2026. · NCT06590857Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
- UT Southwestern, Dallas
Тражи се учесник
Узраст од 18 до 80 · Жене · Ажурирано 12. 11. 2026. · NCT05245812A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Baylor Scott & White Research Institute -Texas Oncology, Dallas
- UT Southwestern Medical Center, Dallas
- South Texas Accelerated Research Therapeutics (START), LLC, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06827236Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- M D Anderson Cancer Center, Houston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT03941756A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Texas Oncology - DFW ( Site 8009), Dallas
- UT Southwestern ( Site 0092), Dallas
- Texas Oncology - Northeast Texas ( Site 8002), Flower Mound
- и још 6
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06966700Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT04557449ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- University of Texas Southwestern Medical Center, Dallas
- Houston Methodist Cancer Center, Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07007559Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
- UT Southwestern Medical Center, Dallas
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT05693766Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
- MD Anderson Cancer Center, Houston
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT05964504A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07029399Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06324357A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center - Conroe, Conroe
- The University of Texas - M.D. Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
- и још 3
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07318805Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Houston Methodist Hospital, Houston
- Oncology Consultants, Houston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07214532Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Texas Oncology Central/South, Austin
- Texas Oncology DFW, Dallas
- University of Texas Southwestern Medical Center, Dallas
- и још 3
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06982521A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Hendrick Medical Center, Abilene
- World Research Link, Baytown
- Parkland Health and Hospital System, Dallas
- и још 10
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07174336A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- JPS Health Network, Fort Worth
- Community Clinical Trials, Spring
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06790693E-Mindfulness Approaches for Living After Breast Cancer
- The Don and Sybil Harrington Cancer Center, Amarillo
Тражи се учесникФаза 3
Узраст од 18 до 50 · Оба пола · Ажурирано 4. 11. 2026. · NCT06748222A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Texas MD Anderson Cancer Center, Houston
- Houston Methodist Hospital, Houston
- Oncology Consultants P.A., Houston
- и још 1
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 4. 11. 2026. · NCT07287098Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Texas Oncology, Abilene
- Texas Oncology - Central / South Texas, Austin
- Mary Crowley Cancer Research, Dallas
- и још 3
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The University of Texas - MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06400472A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Texas Oncology - DFW (Sammons CC), Dallas
- Baylor College of Medicine, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07213791A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Texas Oncology - DFW (Sammons CC), Dallas
- MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07114601A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06760819Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- The Don and Sybil Harrington Cancer Center, Amarillo
- Houston Methodist San Jacinto Hospital, Baytown
- UT MD Anderson - The Woodlands, Conroe
- и још 19
Тражи се учесникФаза 3
Узраст од 18 до 60 · Жене · Ажурирано 4. 11. 2026. · NCT05879926A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Texas Oncology - DFW, Dallas
- MD Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06695845A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Texas Oncology - DFW ( Site 8003), Dallas
- JPS Health Network ( Site 0067), Fort Worth
- Texas Oncology - Gulf Coast ( Site 8006), Houston
- и још 3
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07060807A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
- South Texas Accelerated Research Therapeutics, LLC (START), San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Жене · Ажурирано 3. 11. 2026. · NCT07524855A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- MD Anderson Cancer Center, Houston
- NEXT Dallas, Irving
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07578571Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.